Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response

Despite recent advances in cancer immunotherapy, no prospectively validated intermediate biomarkers exist to predict response. These biomarkers are highly desirable given modern immunotherapy’s paradoxical pattern of clinical benefit; that is, improvement in overall survival without short-term chang...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joseph W., Bilusic, Marijo, Heery, Christopher J., Madan, Ravi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712729/
https://www.ncbi.nlm.nih.gov/pubmed/24213505
http://dx.doi.org/10.3390/cancers4041229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712729/
https://www.ncbi.nlm.nih.gov/pubmed/24213505
http://dx.doi.org/10.3390/cancers4041229

Ejemplares similares